Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 680-685, 2006. First published February 23, 2006; 10.1373/clinchem.2005.062562
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.062562v1
52/4/680    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by St. Peter, J. V.
Right arrow Articles by Apple, F. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by St. Peter, J. V.
Right arrow Articles by Apple, F. S.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:680-685.)
© 2006 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass Surgery

John V. St. Peter1,3,a, Guilford G. Hartley2,3, MaryAnn M. Murakami4 and Fred S. Apple2,4

1 College of Pharmacy and 2 School of Medicine, University of Minnesota, Minneapolis, MN.
Departments of3 Medicine and 4 Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN.

aAddress correspondence to this author at: Experimental & Clinical Pharmacology, University of Minnesota, College of Pharmacy, Weaver Densford Hall 7-115A, 308 Harvard Street SE, Minneapolis, MN 55455-0343. Fax 612-625-3927; e-mail stpet003{at}umn.edu.

Background: Further investigations are warranted to better characterize variables that may confound the clinical interpretation of plasma natriuretic peptide measurements, which are increasingly recognized to have diagnostic and predictive importance.

Methods: Blood samples (EDTA plasma) from patients (n = 206) attending clinics for the medical treatment and follow-up of obesity were analyzed for B-type natriuretic peptide (BNP; Bayer assay) and the N-terminal segment of its prohormone (NT-proBNP; Roche assay). Natriuretic peptide concentration ranges were evaluated in those without diagnosis of congestive heart failure (CHF) or chronic kidney disease (CKD).

Results: BNP and NT-proBNP were directly correlated (r = 0.87; P = 0.01), with NT-proBNP concentrations higher relative to BNP. Of obese patients without CHF or CKD, 21.6% (40 of 185) had NT-proBNP concentrations greater than the published assay upper reference limit. Concentrations of both natriuretic peptides were higher in patients currently exposed to beta blockers, patients with the diagnosis of hypertension or type 2 diabetes, and patients with a history of gastric bypass surgery. An inverse relationship between body mass index (BMI) and both BNP and NT-proBNP was evident. According to the National Institutes of Health, National Heart, Lung, and Blood Institute classification, more than 95% of the participants sampled in this study were either obesity class 2 (35 kg/m2 < BMI < 39.9 kg/m2) or class 3 (BMI ≥40 kg/m2)

Conclusions: A substantial proportion of obese patients without CHF or CKD have concentrations greater than the upper reference limit for NT-proBNP but not for simultaneously measured BNP. A history of gastric bypass surgery appeared to be a significant predictor of increased natriuretic peptide concentrations when assessed in a population of patients with class 2 or 3 obesity.




The following articles in journals at HighWire Press have cited this article:


Home page
 Eur Heart J SupplHome page
A. Fijalkowska and A. Torbicki
Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H41 - H47.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure
Circulation, July 31, 2007; 116(5): e95 - e98.
[Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
S. Choi, D. Park, S. Lee, Y. Hong, S. Kim, and J. Lee
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments
Emerg. Med. J., May 1, 2007; 24(5): 343 - 347.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.